Daily Brief Archive: August 4, 2026 — U.S. & Hong Kong Stock Analysis
Free previewU.S. Markets
- Iran de-escalation sent crude down over 5%; risk appetite returned across the board
- Dow hit a record 53,178; S&P 500 +1.48%, Nasdaq +2.1%
- Microsoft added roughly $450B in one session — the largest single-day gain in US history
- Morgan Stanley blessed AI capex; META +6%, GOOGL +4.9%
- Apple bucked the tape at -1.78% as memory inflation bites margins and supply
- AstraZeneca -6.88%: a rumored $400B megamerger was punished, not rewarded
Hong Kong
- Hang Seng +0.48% back above 26,000; HS Tech +0.96%
- Southbound net buying of HK$11.03B rotated back into platforms
- Alibaba +7.01% to 125.2 on the 2.4T-parameter Qwen3.8 launch
- WuXi AppTec lifted FY guidance to RMB58.5–60.5B; A/H shares ripped
- CXO names rallied together: WuXi Bio +4.4%, Pharmaron +7.9%
- Semis lagged all session; the Kingboard complex stayed pinned in oversold territory
Today's Watchlist
- PLTR posted $0.41 EPS vs $0.28 est., revenue +92.8% after the close
- SNDK reports FQ4 on 8/5, right after defending the $1,000 shelf
- WuXi AppTec's H-shares spiked more than 14% intraday on 8/4
- ATKR agreed to Prysmian's $95/share all-cash bid; the arb spread has narrowed
- If AZN/BMY advances, antitrust review is the dominant variable
- Memory inflation cuts both ways: a tailwind for MU/SNDK, a headwind for AAPL
Deep Dives (0 names)
No deep-dive names match the current filters
Rapid Scan (9 names)
| Ticker | Close | Change | Score | Direction | One-line take |
|---|---|---|---|---|---|
| $93.55 | +28.22% | 6 | Neutral | Up 28.22% on Prysmian's $95/share all-cash bid plus a Q3 beat. At $93.55 the stock sits just 1.5% below the offer, so the arbitrage is effectively closed; sidelines. | |
| $124.45 | +2.67% | 6 | Neutral | Up 2.67% to a 52-week high on the board's highest relative volume at 20.69x — but RSI at 84.9 is extremely overbought and the breakout's risk/reward has flipped; sidelines. | |
| $87.31 | +4.63% | 6 | Neutral | Up 4.63% to a $87.63 52-week high and 26.3% on the month on a clear CGM demand trend — but RSI at 72.6 is overbought and a pullback toward the 20-day near $80 would be a better entry; sidelines. | |
| $126.17 | +3.18% | 6 | Neutral | Up 3.18% to a 52-week high and 19.4% on the month with RSI still healthy at 64.6. The annuity book benefits from the rate backdrop, but there was no standalone catalyst today; sidelines. | |
| $40.54 | +2.87% | 5 | Neutral | Up 2.87% to a $41.03 52-week high with RSI at 64.3 — but the long-running user-growth problem is unresolved and the breakout lacks fundamental confirmation; sidelines. | |
| $172.94 | +2.63% | 5 | Neutral | Up 2.63% toward its 52-week high with RSI overbought at 70.9 after a 15.7% month — a medical-device recovery trade without standalone news; sidelines. | |
| $115.22 | +2.40% | 5 | Neutral | Up 2.4% toward the $118.30 high with a healthy RSI of 60.5; life-science tools demand is recovering alongside CXO, but the move already reflects it; sidelines. | |
| $58.04 | +5.89% | 5 | Neutral | Up 5.89% to a 52-week high on 4.07x relative volume with RSI at 70.2 — a clinical-stage biotech breakout with no fundamental anchor; sidelines. | |
| $20.99 | +8.36% | 5 | Neutral | Up 8.36% to a 52-week high on 2.66x volume after a 17.4% month — an AUM-driven move without standalone news today; sidelines. |